New Jersey blood cancers conference open to the public

If you're in or around the New Jersey area on September 26, 2009 and want to hear what some of the nation's top lymphoma experts have to say, and maybe even corner one or two of them to get answers to some of your pressing questions, check out the Hematological Malignancies Conference at the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, NJ.

The conference, which is geared towards health professionals and is co-hosted by the Leukemia & Lymphoma Society, is open to the public. If you're interested in checking it out, contact David Marisol at 201-996-2515 or marisoldavid@humed.com.

Time, date, location

Time: 8 am to 2:30 pm
Date: Saturday, September 26, 2009
Location: The Hekemian Conference Center Auditorium, Hackensack University Medical Center, 30 Prospect Ave., Hackensack, New Jersey.

Featured speakers

Andre Goy, M.D. - Deputy Director, John Theurer Cancer Center, Chief, Division of Lymphoma; Director, Cancer Research
Wyndham Wilson, M.D., Ph.D. - National Cancer Institute, Chief, Lymphoma Therapeutics, Metabolic Branch, Center for Cancer Research
Carol Portlock, M.D. - Memorial Sloane-Kettering Cancer Center, Professor of Medicine, Attending Physician of Lymphoma
Rafael Fonseca, M.D. - Mayo Clinic, Professor of Medicine, Deputy Director of Mayo Clinic Cancer Center
Robert J. Soiffer, M.D. - Dana Farber Cancer Institute, Harvard Medical Professor of Medicine, Harvard Medical School, Chief Division of Blood Centers

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap